Search

everythinglearnresearchcommunity

for

Search:↓

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

A user's progress with using Minoxidil, finasteride, and microneedling to treat hair loss; another user mentioned a Japanese study that found better results for hairy individuals on finasteride.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hair follicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.

A user shared 3-month hair regrowth results using a combination of oral Dutasteride, daily Minoxidil, RU58841, micro-needling, Keto shampoo, scalp massages, and supplements. Positive progress was noted, and encouragement to continue was given.

Using lice as an alternative to microneedling for hair loss treatment, with concerns about effectiveness and practicality. Some users humorously suggest genetically altering lice to produce beneficial compounds.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

The user is using Nioxin, various supplements, and natural oils for hair regrowth. They are not using Minoxidil, finasteride, or RU58841.

Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.

The user shared a 3-year hair restoration update using 0.5mg dutasteride daily, 5% minoxidil foam twice daily, a 1.5mm derma roller twice a month, and Nizoral shampoo. They reported significant improvement and maintenance of hair, with minimal side effects, and are satisfied with the results at age 40.

Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Microneedling can cause a sneezing reflex due to tingling in the nose. Users report this reaction, especially in the temple region.

A user is treating their advanced hair loss with a regimen including topical finasteride, minoxidil, hydrocortisone, stem cell serum, peptide serum, multivitamins, he shou wu tea, derma pen, argan oil, and a derma roller. Replies suggest it's too early to judge progress and recommend staying consistent, with one suggesting oral minoxidil as an additional option.

The progress of Phase I of HMI-115, a potential hair loss treatment, which consists of Minoxidil, finasteride, and RU58841. The estimated completion date is June.

Microneedling, when combined with finasteride and topical minoxidil, can enhance hair regrowth for male pattern baldness, especially at the temples. Users report varying success with needle depths between 0.5mm and 1.5mm, with stamps preferred over rollers to minimize scalp damage.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation is about personal experiences with Nifeishi rosemary mint oil for hair loss and requests for an ingredient review to assess its quality. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

Microneedling at depths greater than 0.6 mm may damage miniaturized hair follicles, with 0.5 mm showing better results for hair regrowth. Combining microneedling with minoxidil enhances absorption, but caution is advised to avoid damaging follicles.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

A humorous discussion about a newborn's hair loss, jokingly suggesting treatments like Minoxidil, finasteride, and various other hair loss remedies. Participants humorously debate extreme measures, including shaving or using a "nuclear stack" of treatments.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.